- Home
- Quality Improvement
- COVID-19 & CVD QI Programme Introduction
- COVID-19 QI Programme Module 3
Module 3: Interventions, guidelines and treatment options
This programme has been funded by Pfizer Ltd by an independent medical educational grant. Pfizer were not involved in the development of the programme, content, selection of speakers or their arrangements. All content has been independently developed by the PCCS.
The content was filmed prior to the 26 February 2026 update to the NICE guidelines, removing the recommendation on sotrovimab because the company has discontinued manufacturing, supply, distribution and marketing of sotrovimab in the UK.
The information provided in this presentation is for educational purposes only. Prescribing or management decisions made by clinicians are exclusively their own responsibility. The speaker/PCCS bear no responsibility regarding management or prescribing decisions made by others, or otherwise.
Resources and Useful Links
Thank you for completing the COVID-19 & CVD QI Programme.